Why the study?
Is limited genetic screening of the TNNT2 gene useful for routine testing of disease-causing mutations in patients with HCM and DCM?
Is limited genetic screening of the TNNT2 gene useful for routine testing of disease-causing mutations in patients with HCM and DCM?
Limited genetic screening of the TNNT2 gene yields a low rate of unique disease-causing mutations and is not recommended for routine clinical practice in patients with HCM and DCM.
Low TNNT2 mutation yield in HCM/DCM; leaves open routine screening utility and requires prospective validation before practice change.
Mutations in troponin T (TNNT2) gene represent the important part of currently identified disease-causing mutations in hypertrophic (HCM) and dilated (DCM) cardiomyopathy. The aim of this study was to analyze TNNT2 gene exons in patients with HCM and DCM diagnosis to improve diagnostic and genetic consultancy in affected families. All 15 exons and their flanking regions of the TNNT2 gene were analyzed by DNA sequence analysis in 174 patients with HCM and DCM diagnosis. We identified genetic variations in TNNT2 exon regions in 56 patients and genetic variations in TNNT2 intron regions in 164 patients. Two patients were found to carry unique mutations in the TNNT2 gene. Limited genetic screening analysis is not suitable for routine testing of disease-causing mutations in patients with HCM and DCM as only individual mutation-positive cases may be identified. Therefore, this approach cannot be recommended for daily clinical practice even though, due to financial constraints, it currently represents the only available strategy in a majority of cardio-centers.
No takes yet. Share an insight, caveat, or question.
Jáchymová et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: